Trial · NCT02065791
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death | Placebo | 61.24 | Event rate per 1000 participant-years | ||
| Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death | Canagliflozin 100 mg | 43.21 | Event rate per 1000 participant-years | ||
| Composite Endpoint of CV Death and Hospitalized Heart Failure (HHF) | Placebo | 45.44 | Event rate per 1000 participant-years | ||
| Composite Endpoint of CV Death and Hospitalized Heart Failure (HHF) | Canagliflozin 100 mg | 31.47 | Event rate per 1000 participant-years | ||
| Major Adverse Cardiac Event (MACE) | Placebo | 48.67 | Event rate per 1000 participant-years | ||
| Major Adverse Cardiac Event (MACE) | Canagliflozin 100 mg | 38.71 | Event rate per 1000 participant-years | ||
| Hospitalized Heart Failure (HHF) | Placebo | 25.33 | Event rate per 1000 participant-years | ||
| Hospitalized Heart Failure (HHF) | Canagliflozin 100 mg | 15.65 | Event rate per 1000 participant-years | ||
| Renal Composite Endpoint | Placebo | 40.36 | Event rate per 1000 participant-years | ||
| Renal Composite Endpoint | Canagliflozin 100 mg | 26.99 | Event rate per 1000 participant-years | ||
| Cardiovascular (CV) Death | Placebo | 24.38 | Event rate per 1000 participant-years | ||
| Cardiovascular (CV) Death | Canagliflozin 100 mg | 19.01 | Event rate per 1000 participant-years | ||
| All-cause Mortality | Placebo | 35.00 | Event rate per 1000 participant-years | ||
| All-cause Mortality | Canagliflozin 100 mg | 29.04 | Event rate per 1000 participant-years | ||
| CV Composite Endpoint | Placebo | 66.95 | Event rate per 1000 participant-years | ||
| CV Composite Endpoint | Canagliflozin 100 mg | 49.35 | Event rate per 1000 participant-years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02065791/results